Inhibikase Therapeutics, Inc. (IKT) Q1 2025 Annual Earnings
IKT·Reported May 14, 2025·Before market open
Diluted EPS came in at $-0.15 (+79.5% YoY), missed the $-0.11 consensus by $0.04.
Diluted EPS
$-0.15missed by $0.04
Consensus: $-0.11
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Inhibikase Therapeutics, Inc.'s Q1 2025 earnings report.
Inhibikase Therapeutics, Inc. (IKT) reported Q1 2025 earnings on May 14, 2025 before market open.
Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.15 for Q1 2025.
EPS missed the consensus estimate of $-0.11 by $0.04.
Compared to the same quarter a year prior, diluted EPS grew 79.5% from $-0.73.
You can read the 10-K/A periodic report (0000950170-25-058693) directly on SEC EDGAR. The filing index links above go to sec.gov.